Search
Policy & advocacy
Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.
Read morePresidential Speakers
Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available.
Friday, June 13, 2025 - Presidential Session I
Immunotherapy (TCR related)
Prof.
First CMML guidelines produced by EHA, now available
Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.
Read moreAddressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA
In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.
Read moreHow to apply for the EHA Mentorship Program
EHA Portal accountTo apply, either as a mentor or a mentee, you must be registered on the EHA Portal (Fluxx).
Read more